Interpace Dx Gets Additional Time to Comply With Nasdaq Listing Requirements | GenomeWeb

NEW YORK (GenomeWeb) – Interpace Diagnostics has received notification from Nasdaq that it has been granted an additional 180 days to come into compliance with listing requirements for the exchange, the firm said in a document filed today with the US Securities and Exchange Commission.

The Parsippany, New Jersey-based firm received notice from Nasdaq in January 2016 that it did not meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.